Nanoparticle Delivery Systems for DNA/RNA and Their Potential Applications in Nanomedicine
Overview
Authors
Affiliations
The rapid development of nanotechnology has a great influence on the fields of biology, physiology, and medicine. Over recent years, nanoparticles have been widely presented as nanocarriers to help the delivery of gene, drugs, and other therapeutic agents with cellular targeting ability. Advances in the understanding of gene delivery and RNA interference (RNAi)-based therapy have brought increasing attention to understanding and tackling complex genetically related diseases, such as cancer, cardiovascular and pulmonary diseases, autoimmune diseases and infections. The combination of nanocarriers and DNA/RNA delivery may potentially improve their safety and therapeutic efficacy. However, there still exist many challenges before this approach can be practiced in the clinic. In this review, we provide a comprehensive summary on the types of nanoparticle systems used as nanocarriers, highlight the current use of nanocarriers in recombinant DNA and RNAi molecules delivery, and the current landscape of gene-based nanomedicine-ranging from diagnosis to therapeutics. Finally, we briefly discuss the biosafety concerns and limitations in the preclinical and clinical development of nanoparticle gene systems.
Wang Q, Xue X, Wang P, Yu Y, Wang J, Jiang Q Front Pharmacol. 2024; 15:1435282.
PMID: 39415837 PMC: 11479923. DOI: 10.3389/fphar.2024.1435282.
Hou J, Jie J, Wei X, Shen X, Zhao Q, Chai X J Nanobiotechnology. 2024; 22(1):449.
PMID: 39080658 PMC: 11287882. DOI: 10.1186/s12951-024-02675-2.
Ottonelli I, Adani E, Bighinati A, Cuoghi S, Tosi G, Vandelli M Int J Nanomedicine. 2024; 19:4235-4251.
PMID: 38766661 PMC: 11102183. DOI: 10.2147/IJN.S457302.
The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects.
Lu B, Lim J, Yu B, Song S, Neeli P, Sobhani N Front Immunol. 2024; 15:1332939.
PMID: 38361919 PMC: 10867258. DOI: 10.3389/fimmu.2024.1332939.
iRGD-Targeted Peptide Nanoparticles for Anti-Angiogenic RNAi-Based Therapy of Endometriosis.
Egorova A, Petrosyan M, Maretina M, Bazian E, Krylova I, Baranov V Pharmaceutics. 2023; 15(8).
PMID: 37631322 PMC: 10459007. DOI: 10.3390/pharmaceutics15082108.